Management of Tuberculosis with Rifampicin Intolerance

Recommended Treatment Approach

• The American Thoracic Society recommends continuing ethambutol and pyrazinamide, and adding isoniazid if not contraindicated, for a patient with tuberculosis who has developed intolerance to rifampicin 1, 2
• The treatment regimen should consist of isoniazid, ethambutol, pyrazinamide, and a fluoroquinolone for a total duration of 18 months, as recommended by the British Thoracic Society 1

Rationale for Treatment Duration

• The World Health Organization suggests that isolated rifampicin resistance or intolerance requires an extension of treatment to 18 months total, which typically consists of 2 months of isoniazid, pyrazinamide, and ethambutol followed by 16 months of isoniazid plus ethambutol 1, 2

Monitoring Recommendations

• The European Respiratory Society recommends monthly clinical evaluations with sputum smear and culture monitoring until conversion, and regular liver function tests, especially if continuing pyrazinamide long-term 3, 4, 5
• The Centers for Disease Control and Prevention suggest that treatment should be continued until at least 12 months after culture conversion 1

Common Pitfalls to Avoid

• The Infectious Diseases Society of America advises against adding a single drug to a failing regimen, as this can lead to additional drug resistance, and against shortening the treatment duration below 18 months when rifampicin cannot be included in the regimen 4, 1, 2

Special Considerations

• The American College of Chest Physicians recommends considering alternative agents such as cycloserine, ethionamide, or aminoglycosides after consultation with TB specialists if the patient develops intolerance to other first-line drugs 1, 2
• The European Respiratory Society suggests regular adherence monitoring and consideration of directly observed therapy (DOT) to ensure compliance with this lengthy treatment course 3